Semaglutide had a 42% lower risk of worsening mental health, while liraglutide was linked to an 18% lower risk
Mayo Clinic and Cleveland Clinic resources caution against non-FDA approved uses, citing lack of standardization and purity in non-pharmaceutical sources [mayoclinic.org], [my.clevelandclinic.org]
What is Tapering Off GLP-1s
Patients with metabolic dysfunction-associated steatotic liver disease (MASLD, formerly NAFLD) and insulin resistance may experience improvements in hepatic steatosis and liver enzyme elevations, though this represents an off-label use with evolving evidence
You complete a health assessment, a provider reviews your information, and if approved, your medication ships directly to you
doi: 10.1073/pnas.1219451110 46 RemelyMHippeBZannerJAumuellerEBrathHHaslbergerAG